- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
[BioSante Pharmaceuticals, Inc. Letterhead]
March 13, 2012
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: |
| BioSante Pharmaceuticals, Inc. |
|
| File No. 001-31812 |
Ladies and Gentlemen:
We are hereby furnishing for filing via EDGAR BioSante Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended December 31, 2011.
Pursuant to General Instruction D.(3) of Form 10-K, BioSante hereby represents that the financial statements included in the Form 10-K do not reflect a change from the preceding fiscal year in any accounting principles or practices or in the method of applying such principles or practices other than any change made in response to a standard adopted by the Financial Accounting Standards Board.
Any questions or comments regarding this filing may be directed to the undersigned at (847) 478-0500 ext. 101.
Very truly yours,
/s/ Phillip B. Donenberg |
|
|
|
Phillip B. Donenberg |
|
Senior Vice President of Finance, Chief Financial Officer and Secretary |
cc: Amy E. Culbert, Esq.